• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Implantica

58.30 SEK

+5.23 %

Less than 1K followers

IMP A SDB

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+5.23 %
+33.72 %
+43.95 %
+16.37 %
+12.77 %
+45.21 %
+192.96 %
-44.48 %
-39.62 %

Implantica operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio is broad and includes implantable medical instruments, which are also used for the treatment of diseases affecting the esophagus. In addition to the main business, related ancillary services are offered, particularly focused on eHealth. The business is operated globally with the largest presence in North America and Europe.

Read more
Market cap
68.98B SEK
Turnover
1.16M SEK
Revenue
22.39M
EBIT %
-990.01 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
ShowingAll content types

Forum discussions
Implantica’s RefluxStop® sparked great enthusiasm at the American Foregut Society meeting in the United States ahead of the expected FDA approval. Medtech company Implantica presented its RefluxStop® implant, developed for the treatment of acid reflux, at the AFS annual meeting in...
9/17/2025, 6:49 AM
by Pevitaha
4
Vahva on luotto firmalla, että FDA hyväksyntä tulee, kun on kehitetty uusi tuotantolaite jolla saadaan nopeammin valmistettua RefluxStopia. Implantica finishes new multi-cavity production tool for RefluxStop® to support manufacturing ramp-up in the U.S. pending FDA approval logo ...
8/13/2025, 6:59 AM
by Pevitaha
3
implantica.com Implantica submits final response to FDA in the PMA application for... Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment...
5/20/2026, 10:03 AM
by Pevitaha
2
Implanticas Q3’25 webcast: Inderes Implantica, Webcast, Q3'25 - Inderes Time: 2025-10-31 15:00 Language: en Language: en Sector: Health care - Pharmaceuticals & Biotechnology Activity: Audiocast with teleconference
11/4/2025, 12:40 PM
by Isa Hudd
2
Toinen julkaisu RefluxStopin viiden vuoden seurannan tuloksista. Eihän tässä voi kuin odotella FDA hyväksynnän tuloksia, jotka toivottavasti tulee tässä lähiaikoina (autumn). implantica.com Implantica announces second publication of groundbreaking 5-year results from... Implantica...
8/7/2025, 7:00 AM
by Pevitaha
2
Tykkään tästä vertailusta toiseen hoitotapaan ja sen mahdollisiin haittavaikutuksien vs RefluxStop. Aika merkittävästi vähemmän haittavaikutuksia esiintyy RefluxStop vs Nissen Implantica announces publication of the landmark RefluxStop® 5-year clinical study results demonstrating...
7/1/2025, 11:47 AM
by Pevitaha
2
Implantica submits the last and final module 3 of the FDA PMA Application for RefluxStop® for US market approval logo Implantica submits the last and final module 3 of the FDA PMA Application for RefluxStop® for US market approval Implantica AG (publ.), a MedTech company at the forefront...
6/24/2025, 6:10 AM
by Pevitaha
2
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
21/8
2026

Interim report Q2'26

19/11
2026

Interim report Q3'26

Regulatory press release6/10/2026, 5:50 PM

Bulletin from the Annual General Meeting of Implantica AG

Implantica
Press release6/9/2026, 6:00 AM

Implantica tillkännager öppnandet av det 20:e RefluxStop® Center of Excellence i Spanien, som ingår i en världsberömd amerikansk sjukhuskoncern

Implantica
Press release6/9/2026, 6:00 AM

Implantica announces launch of 20[th] RefluxStop® Center of Excellence in Spain, part of a world-renowned US hospital group

Implantica

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Implantica, Webcast, Q1'26
Webcast5/22/2026, 1:00 PM

Implantica, Webcast, Q1'26

Implantica
Regulatory press release5/22/2026, 6:00 AM

Implantica publicerar delårsrapport januari - mars 2026 (Q1)

Implantica
Regulatory press release5/22/2026, 6:00 AM

Implantica publishes Interim Report January - March 2026 (Q1)

Implantica
Regulatory press release5/21/2026, 9:00 AM

Notice of Annual General Meeting of Implantica AG

Implantica
Press release5/21/2026, 6:00 AM

Implantica tillkännager publiceringen av en ny hälsoekonomisk studie som visar RefluxStop®'s överlägsna kostnadseffektivitet vid behandling av GERD i det italienska sjukvårdssystemet

Implantica
Press release5/21/2026, 6:00 AM

Implantica announces publication of a new health economics study showing RefluxStop®'s superior cost-effectiveness in the treatment of GERD in the Italian Healthcare System

Implantica
Press release5/20/2026, 6:00 AM

Implantica submits final response to FDA in the PMA application for RefluxStop® for U.S. market approval

Implantica
Press release5/20/2026, 6:00 AM

Implantica lämnar in slutgiltigt svar till FDA gällande PMA-ansökan för RefluxStop® för marknadsgodkännande i USA

Implantica
Press release5/19/2026, 6:01 AM

Implantica tillkännager nya banbrytande långsiktiga RefluxStop®-data om svårt sjuka patienter presenterade på DDW 2026

Implantica
Press release5/19/2026, 6:01 AM

Implantica announces new breakthrough long-term RefluxStop® data on severe sufferers presented at DDW 2026

Implantica
Press release5/19/2026, 6:00 AM

Implantica: RefluxStop® stärker sin position på DDW 2026

Implantica
Press release5/19/2026, 6:00 AM

Implantica: RefluxStop® gains momentum at DDW 2026

Implantica
Press release5/18/2026, 7:00 AM

Implantica presents the first quarter (Q1 2026) on May 22 at 15:00 CET

Implantica
Press release5/18/2026, 7:00 AM

Implantica presenterar första kvartalet (Q1 2026), den 22 maj kl. 15:00 CET

Implantica
Regulatory press release5/6/2026, 6:00 AM

Implantica publishes Annual Report 2025

Implantica
Press release4/21/2026, 6:00 AM

Implantica announces landmark RefluxStop[® ]study of 602 patients across 22 European centers, with up to 6.75-year follow-up, published in Nature's Scientific Reports

Implantica
Press release4/21/2026, 6:00 AM

Implantica tillkännager den banbrytande RefluxStop[®]-studien med 602 patienter från 22 europeiska center och upp till 6,75 års uppföljning, publicerad i Nature's Scientific Reports

Implantica